BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438-1445. [PMID: 18720527 DOI: 10.1002/cncr.23775] [Cited by in Crossref: 82] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin 2011;27:55-62. [PMID: 21083514 DOI: 10.1185/03007995.2010.535511] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
2 Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int 2012;12:48. [PMID: 23173568 DOI: 10.1186/1475-2867-12-48] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
3 Villemain A, Ribeiro Baptista B, Paillot N, Soudant M, Menard O, Martinet Y, Tiotiu A. [Predictive factors for skeletal-related events in lung cancer]. Rev Mal Respir 2020;37:111-6. [PMID: 31864882 DOI: 10.1016/j.rmr.2019.11.647] [Reference Citation Analysis]
4 Rodríguez-Antolín A, Gómez-Veiga F, Alvarez-Osorio JK, Carballido-Rodriguez J, Palou-Redorta J, Solsona-Narbón E, Sánchez-Sánchez E, Unda M. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options. Actas Urol Esp 2014;38:263-9. [PMID: 24156932 DOI: 10.1016/j.acuro.2013.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
5 Jeon HL, Oh IS, Baek YH, Yang H, Park J, Hong S, Shin JY. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma. J Bone Miner Metab 2020;38:254-63. [PMID: 31673791 DOI: 10.1007/s00774-019-01052-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Snedecor SJ, Carter JA, Kaura S, Botteman MF. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Clin Ther 2012;34:1334-49. [PMID: 22578308 DOI: 10.1016/j.clinthera.2012.04.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
7 De Castro J, García R, Garrido P, Isla D, Massuti B, Blanca B, Vázquez J. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. Clin Lung Cancer 2015;16:431-46. [PMID: 26264596 DOI: 10.1016/j.cllc.2015.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
8 Voss PJ, Stoddart M, Ziebart T, Zeiter S, Nelson K, Bittermann G, Schmelzeisen R, Poxleitner P. Zoledronate induces osteonecrosis of the jaw in sheep. J Craniomaxillofac Surg 2015;43:1133-8. [PMID: 26154396 DOI: 10.1016/j.jcms.2015.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
9 Campagnaro E, Reimers MA, Qin A, Alva AS, Schneider BJ, Van Poznak CH. Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice. JOP 2018;14:457-64. [DOI: 10.1200/jop.18.00236] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 2014;22:1363-73. [PMID: 24389827 DOI: 10.1007/s00520-013-2094-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
11 Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 2013;21:3279-86. [PMID: 23884473 DOI: 10.1007/s00520-013-1887-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 56] [Article Influence: 9.9] [Reference Citation Analysis]
12 Hagiwara M, Delea TE, Cong Z, Chung K. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer 2014;22:103-13. [PMID: 24000042 DOI: 10.1007/s00520-013-1951-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
13 Qian Y, Bhowmik D, Kachru N, Hernandez RK. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Support Care Cancer 2017;25:1845-51. [PMID: 28120114 DOI: 10.1007/s00520-017-3583-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
14 Monteserin L, Mesa A, Fernandez-Garcia MS, Gadanon-Garcia A, Rodriguez M, Varela M. Bone metastases as initial presentation of hepatocellular carcinoma. World J Hepatol 2017;9:1158-65. [PMID: 29085559 DOI: 10.4254/wjh.v9.i29.1158] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Takeda N, Isu K, Hiraga H, Shinohara N, Minami A, Kamata H. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up. J Orthop Sci 2012;17:770-4. [PMID: 23053582 DOI: 10.1007/s00776-012-0294-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
16 Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, Wouters C, Wildiers H. Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Support Care Cancer 2013;21:3483-90. [PMID: 23955094 DOI: 10.1007/s00520-013-1934-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
17 Costa L, Lipton A, Hadji P, Chen Y, Kosmidis P. Treatment of bone metastases before the onset of pain. Int J Clin Oncol 2013;18:531-8. [DOI: 10.1007/s10147-012-0414-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
18 Jahanzeb M, Hirsh V. Bisphosphonates in Lung Cancer: More Than a Palliative Therapy? Seminars in Oncology 2010;37:S45-52. [DOI: 10.1053/j.seminoncol.2010.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Saad F, Fleshner NE, So A, Le Lorier J, Perrault L, Poulin-Costello M, Rogoza R, Robson EJD. The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres. Can Urol Assoc J 2018. [PMID: 29940132 DOI: 10.5489/cuaj.5053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. The Breast 2012;21:544-9. [DOI: 10.1016/j.breast.2012.04.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
21 Félix J, Andreozzi V, Soares M, Borrego P, Gervásio H, Moreira A, Costa L, Marcelo F, Peralta F, Furtado I, Pina F, Albuquerque C, Santos A, Passos-coelho J. Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System. Value in Health 2011;14:499-505. [DOI: 10.1016/j.jval.2010.11.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
22 Lothgren M, Ribnicsek E, Schmidt L, Habacher W, Lundkvist J, Pfeil AM, Biteeva I, Vrouchou P, Bracco A. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm 2013;20:227-31. [PMID: 23888248 DOI: 10.1136/ejhpharm-2012-000235] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
23 Hong S, Youk T, Lee SJ, Kim KM, Vajdic CM. Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study. PLoS One 2020;15:e0234927. [PMID: 32678818 DOI: 10.1371/journal.pone.0234927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
24 Koo K, Lam K, Mittmann N, Konski A, Dennis K, Zeng L, Lam H, Chow E. Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Support Care Cancer 2013;21:1785-91. [PMID: 23519570 DOI: 10.1007/s00520-013-1790-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 Virk MS, Alaee F, Petrigliano FA, Sugiyama O, Chatziioannou AF, Stout D, Dougall WC, Lieberman JR. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone 2011;48:578-87. [PMID: 21073986 DOI: 10.1016/j.bone.2010.11.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
26 Rucci N, Angelucci A. Prostate cancer and bone: the elective affinities. Biomed Res Int 2014;2014:167035. [PMID: 24971315 DOI: 10.1155/2014/167035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
27 Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2011;57:275-82. [PMID: 21671363 DOI: 10.1002/pbc.22821] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
28 Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, Despiegel N, Hechmati G. Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 2020;23:37-47. [DOI: 10.1080/13696998.2019.1651122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
29 Hadji P. Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease. Critical Reviews in Oncology/Hematology 2011;80:301-13. [DOI: 10.1016/j.critrevonc.2011.03.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
30 Hadji P, Gnant M, Aapro M, Lipton A, Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 2011;79:175-88. [PMID: 20846875 DOI: 10.1016/j.critrevonc.2010.07.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
31 Lipton A. Zoledronic acid: multiplicity of use across the cancer continuum. Expert Review of Anticancer Therapy 2014;11:1001-14. [DOI: 10.1586/era.11.71] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
32 Schulman KL, Berenson K, Tina Shih YC, Foley KA, Ganguli A, de Souza J, Yaghmour NA, Shteynshlyuger A. A checklist for ascertaining study cohorts in oncology health services research using secondary data: report of the ISPOR oncology good outcomes research practices working group. Value Health 2013;16:655-69. [PMID: 23796301 DOI: 10.1016/j.jval.2013.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
33 Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 2012;4:85-101. [PMID: 22496711 DOI: 10.1177/1756287212441234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
34 Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol. 2011;6:576-582. [PMID: 21270669 DOI: 10.1097/jto.0b013e318206a1e3] [Cited by in Crossref: 75] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
35 Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology 2013;14:663-70. [DOI: 10.1016/s1470-2045(13)70174-8] [Cited by in Crossref: 122] [Cited by in F6Publishing: 41] [Article Influence: 15.3] [Reference Citation Analysis]
36 Kennedy L, Bhatta S, Hechmati G, Buchanan J. Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases. JCO 2018;36:1051-1051. [DOI: 10.1200/jco.2017.77.0115] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Pautke C, Kreutzer K, Weitz J, Knödler M, Münzel D, Wexel G, Otto S, Hapfelmeier A, Stürzenbaum S, Tischer T. Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model. Bone 2012;51:592-9. [PMID: 22575441 DOI: 10.1016/j.bone.2012.04.020] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
38 Brantus J, Roemer-becuwe C, Cony-makhoul P, Salino S, Fontana A, Debourdeau P, Thomas T, Guastalla J, Ghesquieres H, Sebban C, Pavic M, Collet P, Larbre J, Martinon S, Brocard F, Bodard A, Blanc G, Balestrière V, Favier B, Farsi F, Krakowski I, Biron P. Guide de recommandations d’utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple. La Revue de Médecine Interne 2011;32:494-505. [DOI: 10.1016/j.revmed.2010.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Cristino J, Finek J, Jandova P, Kolek M, Pásztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Journal of Medical Economics 2017;20:799-812. [DOI: 10.1080/13696998.2017.1328423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Mahtani R, Khan R, Jahanzeb M. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer. Clin Lung Cancer 2011;12:26-32. [PMID: 21273176 DOI: 10.3816/CLC.2011.n.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
41 Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J, Kreutzer K, Hohlweg-majert B, Wolff K, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum SR, Kolk A. Fluorescence-Guided Bone Resection in Bisphosphonate-Related Osteonecrosis of the Jaws: First Clinical Results of a Prospective Pilot Study. Journal of Oral and Maxillofacial Surgery 2011;69:84-91. [DOI: 10.1016/j.joms.2010.07.014] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 9.3] [Reference Citation Analysis]
42 Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA. Zoledronic acid in the treatment of metastatic breast cancer. Anticancer Drugs 2014;25:1-7. [PMID: 24100278 DOI: 10.1097/CAD.0000000000000020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
43 Nowicki B, Nehrbass D, Arens D, Stadelmann VA, Zeiter S, Otto S, Kircher P, Stoddart MJ. Medication-related osteonecrosis of the jaw in a minipig model: Parameters for developing a macroscopic, radiological, and microscopic grading scheme. J Craniomaxillofac Surg 2019;47:1162-9. [PMID: 30952472 DOI: 10.1016/j.jcms.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
44 Baek YH, Jeon HL, Oh IS, Yang H, Park J, Shin JY. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study. Cancer Epidemiol 2019;61:104-10. [PMID: 31176960 DOI: 10.1016/j.canep.2019.05.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
45 Hatoum HT, Lin S, Smith MR, Guo A, Lipton A. Treatment Persistence With Monthly Zoledronic Acid is Associated With Lower Risk and Frequency of Skeletal Complications in Patients With Breast Cancer and Bone Metastasis. Clinical Breast Cancer 2011;11:177-83. [DOI: 10.1016/j.clbc.2011.03.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
46 Snaman JM, Baker JN, Ehrentraut JH, Anghelescu DL. Pediatric Oncology: Managing Pain at the End of Life. Paediatr Drugs 2016;18:161-80. [PMID: 26951239 DOI: 10.1007/s40272-016-0168-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
47 Hernandez RK, Quigley J, Pirolli M, Quach D, Chen KS, Arellano J, Liede A. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US. Support Care Cancer 2014;22:2697-705. [PMID: 24789499 DOI: 10.1007/s00520-014-2251-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. Int J Mol Sci 2013;14:10683-93. [PMID: 23702841 DOI: 10.3390/ijms140610683] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
49 Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res 2012;12:425-37. [PMID: 22540167 DOI: 10.1586/erp.12.31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
50 De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, Syrigos K, Trédaniel J. Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel. Journal of Thoracic Oncology 2009;4:1280-8. [DOI: 10.1097/jto.0b013e3181b68e5a] [Cited by in Crossref: 46] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
51 Raje N, Roodman GD, Willenbacher W, Shimizu K, García-sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 2018;21:525-36. [DOI: 10.1080/13696998.2018.1445634] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
52 Goldsby RE, Fan TM, Villaluna D, Wagner LM, Isakoff MS, Meyer J, Randall RL, Lee S, Kim G, Bernstein M, Gorlick R, Krailo M, Marina N. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Eur J Cancer 2013;49:2384-91. [PMID: 23664013 DOI: 10.1016/j.ejca.2013.03.018] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
53 Lu KH, Lu EW, Lin CW, Yang JS, Yang SF. New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma. Pharmacol Ther 2020;214:107611. [PMID: 32565177 DOI: 10.1016/j.pharmthera.2020.107611] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
54 Young J, Nickman NA, Biskupiak JE, Barney RB, Gaffney DK, Namjoshi M, Brandt P. Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid. The Breast 2013;22:495-503. [DOI: 10.1016/j.breast.2012.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]